• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多发性骨髓瘤和前期病变中抗原特异性 T 细胞浸润和空间结构的调控。

Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy.

机构信息

Department of Hematology/Medical Oncology.

Department of Pathology and Laboratory Medicine, and.

出版信息

J Clin Invest. 2023 Aug 1;133(15):e167629. doi: 10.1172/JCI167629.

DOI:10.1172/JCI167629
PMID:37526080
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10378152/
Abstract

Entry of antigen-specific T cells into human tumors is critical for immunotherapy, but the underlying mechanisms are poorly understood. Here, we combined high-dimensional spatial analyses with in vitro and in vivo modeling to study the mechanisms underlying immune infiltration in human multiple myeloma (MM) and its precursor monoclonal gammopathy of undetermined significance (MGUS). Clustered tumor growth was a feature of MM but not MGUS biopsies, and this growth pattern was reproduced in humanized mouse models. MM biopsies exhibited intralesional as well as spatial heterogeneity, with coexistence of T cell-rich and T cell-sparse regions and the presence of areas of T cell exclusion. In vitro studies demonstrated that T cell entry into MM clusters was regulated by agonistic signals and CD2-CD58 interactions. Upon adoptive transfer, antigen-specific T cells localized to the tumor site but required in situ DC-mediated antigen presentation for tumor entry. C-type lectin domain family 9 member A-positive (CLEC9A+) DCs appeared to mark portals of entry for gradients of T cell infiltration in MM biopsies, and their proximity to T cell factor 1-positive (TCF1+) T cells correlated with disease state and risk status. These data illustrate a role for tumor-associated DCs and in situ activation in promoting the infiltration of antigen-specific T cells in MM and provide insights into spatial alterations in tumor/immune cells with malignant evolution.

摘要

抗原特异性 T 细胞进入人体肿瘤对于免疫治疗至关重要,但相关的潜在机制仍不清楚。在这里,我们结合高维空间分析以及体外和体内建模来研究人类多发性骨髓瘤(MM)及其前体意义未明的单克隆丙种球蛋白病(MGUS)中免疫浸润的潜在机制。肿瘤簇集性生长是 MM 活检的特征,但不是 MGUS 活检的特征,这种生长模式在人源化小鼠模型中得到了重现。MM 活检表现出肿瘤内以及空间异质性,存在富含 T 细胞和 T 细胞稀疏的区域共存,以及存在 T 细胞排斥区域。体外研究表明,T 细胞进入 MM 簇的过程受到激动信号和 CD2-CD58 相互作用的调节。在过继转移后,抗原特异性 T 细胞定位于肿瘤部位,但需要原位 DC 介导的抗原呈递才能进入肿瘤。C 型凝集素结构域家族 9 成员 A 阳性(CLEC9A+)DC 似乎标记了 MM 活检中 T 细胞浸润梯度的进入门户,其与 T 细胞因子 1 阳性(TCF1+)T 细胞的接近程度与疾病状态和风险状况相关。这些数据说明了肿瘤相关 DC 和原位激活在促进 MM 中抗原特异性 T 细胞浸润中的作用,并提供了对恶性演变过程中肿瘤/免疫细胞空间改变的深入了解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d36/10378152/9b252a442a80/jci-133-167629-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d36/10378152/ae85a0d0ca2a/jci-133-167629-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d36/10378152/bf846e3a671b/jci-133-167629-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d36/10378152/4f6b1642ec89/jci-133-167629-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d36/10378152/07648a3a0195/jci-133-167629-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d36/10378152/df86425f01f3/jci-133-167629-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d36/10378152/80d8f447b934/jci-133-167629-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d36/10378152/9b252a442a80/jci-133-167629-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d36/10378152/ae85a0d0ca2a/jci-133-167629-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d36/10378152/bf846e3a671b/jci-133-167629-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d36/10378152/4f6b1642ec89/jci-133-167629-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d36/10378152/07648a3a0195/jci-133-167629-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d36/10378152/df86425f01f3/jci-133-167629-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d36/10378152/80d8f447b934/jci-133-167629-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7d36/10378152/9b252a442a80/jci-133-167629-g007.jpg

相似文献

1
Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy.多发性骨髓瘤和前期病变中抗原特异性 T 细胞浸润和空间结构的调控。
J Clin Invest. 2023 Aug 1;133(15):e167629. doi: 10.1172/JCI167629.
2
Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy.骨髓中前肿瘤性丙种球蛋白病中的干细胞样/固有 T 细胞、先天和髓样细胞的早期改变。
JCI Insight. 2019 Apr 23;5(11):127807. doi: 10.1172/jci.insight.127807.
3
The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches.T 细胞免疫在单克隆丙种球蛋白病和多发性骨髓瘤中的作用:从免疫发病机制到新的治疗方法。
Int J Mol Sci. 2022 May 8;23(9):5242. doi: 10.3390/ijms23095242.
4
Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141 dendritic cells to activate naïve and memory NY-ESO-1-specific CD8 T cells.人 CLEC9A 抗体将 NY-ESO-1 抗原递呈给 CD141 树突状细胞,从而激活幼稚和记忆 NY-ESO-1 特异性 CD8 T 细胞。
J Immunother Cancer. 2020 Jul;8(2). doi: 10.1136/jitc-2020-000691.
5
Dendritic cell biology and the application of dendritic cells to immunotherapy of multiple myeloma.树突状细胞生物学及其在多发性骨髓瘤免疫治疗中的应用。
Med Oncol. 2000 Feb;17(1):2-15. doi: 10.1007/BF02826210.
6
Self-adjuvanting nanoemulsion targeting dendritic cell receptor Clec9A enables antigen-specific immunotherapy.靶向树突状细胞受体 Clec9A 的自佐剂纳米乳剂实现抗原特异性免疫治疗。
J Clin Invest. 2018 May 1;128(5):1971-1984. doi: 10.1172/JCI96791. Epub 2018 Apr 9.
7
Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T-cell killing.树突状细胞在骨髓瘤患者的骨髓中聚集,在那里它们保护肿瘤浆细胞免受CD8 + T细胞的杀伤。
Blood. 2015 Sep 17;126(12):1443-51. doi: 10.1182/blood-2015-01-623975. Epub 2015 Jul 16.
8
Differential pattern of CD4+ and CD8+ T-cell immunity to MAGE-A1/A2/A3 in patients with monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma.意义未明的单克隆丙种球蛋白病(MGUS)和多发性骨髓瘤患者中,CD4+和CD8+ T细胞对MAGE-A1/A2/A3免疫反应的差异模式。
Blood. 2008 Oct 15;112(8):3362-72. doi: 10.1182/blood-2008-04-149393. Epub 2008 Jul 24.
9
In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.局部放射治疗原位递送 iPSC 来源的树突状细胞可在临床前免疫原性低的肿瘤模型中产生全身抗肿瘤免疫并增强 PD-L1 阻断作用。
J Immunother Cancer. 2021 May;9(5). doi: 10.1136/jitc-2021-002432.
10
Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen.携带死肿瘤抗原的天然小鼠常规型 1 树突状细胞的有效癌症免疫疗法。
J Immunother Cancer. 2019 Apr 8;7(1):100. doi: 10.1186/s40425-019-0565-5.

引用本文的文献

1
Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement.嵌合抗原受体T细胞(CAR-T)与双特异性抗体在伴有髓外浸润的多发性骨髓瘤中的活性
Blood Cancer J. 2025 Jul 30;15(1):126. doi: 10.1038/s41408-025-01330-9.
2
A potential prognostic marker for hematologic neoplasms: CD58.血液肿瘤的一种潜在预后标志物:CD58。
Front Oncol. 2025 Apr 29;15:1586842. doi: 10.3389/fonc.2025.1586842. eCollection 2025.
3
Spatial imaging unlocks the potential of charting multiple myeloma and extramedullary disease.

本文引用的文献

1
Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections.多发性骨髓瘤患者接种 3 剂 mRNA 疫苗后对 SARS-CoV-2 变异体的中和能力和 CD8+ T 细胞反应受损:与突破性感染的相关性。
Blood Cancer Discov. 2023 Mar 1;4(2):106-117. doi: 10.1158/2643-3230.BCD-22-0173.
2
The immune system in multiple myeloma and precursor states: Lessons and implications for immunotherapy and interception.多发性骨髓瘤及前体状态中的免疫系统:免疫治疗和干预的启示和意义。
Am J Hematol. 2023 Mar;98 Suppl 2(Suppl 2):S4-S12. doi: 10.1002/ajh.26752. Epub 2022 Oct 24.
3
空间成像揭示了绘制多发性骨髓瘤和髓外疾病图谱的潜力。
J Hematol Oncol. 2025 Apr 23;18(1):47. doi: 10.1186/s13045-025-01699-x.
4
Exploring Clec9a in dendritic cell-based tumor immunotherapy for molecular insights and therapeutic potentials.探索Clec9a在基于树突状细胞的肿瘤免疫治疗中的分子见解和治疗潜力。
NPJ Vaccines. 2025 Feb 7;10(1):27. doi: 10.1038/s41541-025-01084-2.
5
Topological importance of CD8 T-cell enrichment in the tumor microenvironment of classic Hodgkin lymphoma.经典型霍奇金淋巴瘤肿瘤微环境中CD8 T细胞富集的拓扑学重要性。
Ann Hematol. 2025 Feb;104(2):1047-1057. doi: 10.1007/s00277-025-06189-1. Epub 2025 Jan 17.
6
Smoldering multiple myeloma: Integrating biology and risk into management.冒烟型多发性骨髓瘤:将生物学特性与风险纳入管理
Semin Hematol. 2025 Feb;62(1):3-10. doi: 10.1053/j.seminhematol.2024.10.002. Epub 2024 Oct 18.
7
Efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: a systematic review and meta-analysis.替西妥单抗治疗复发或难治性多发性骨髓瘤的疗效和安全性:一项系统评价与荟萃分析
Ann Hematol. 2024 Dec;103(12):4901-4912. doi: 10.1007/s00277-024-06078-z. Epub 2024 Nov 8.
8
Revisiting T-cell adhesion molecules as potential targets for cancer immunotherapy: CD226 and CD2.重新审视 T 细胞黏附分子作为癌症免疫治疗的潜在靶点:CD226 和 CD2。
Exp Mol Med. 2024 Oct;56(10):2113-2126. doi: 10.1038/s12276-024-01317-9. Epub 2024 Oct 1.
9
Understanding CAR-T therapy in myeloma: 1 cell at a time.了解骨髓瘤中的嵌合抗原受体T细胞(CAR-T)疗法:一次一个细胞。
Blood Adv. 2024 Jul 9;8(13):3560-3561. doi: 10.1182/bloodadvances.2024013292.
10
Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel.依达卡替尼治疗多发性骨髓瘤髓外病变的疗效分析
J Hematol Oncol. 2024 Jun 6;17(1):42. doi: 10.1186/s13045-024-01555-4.
Changes in Bone Marrow Tumor and Immune Cells Correlate with Durability of Remissions Following BCMA CAR T Therapy in Myeloma.
骨髓肿瘤和免疫细胞的变化与骨髓瘤患者接受 BCMA CAR T 治疗后的缓解持续时间相关。
Blood Cancer Discov. 2022 Nov 2;3(6):490-501. doi: 10.1158/2643-3230.BCD-22-0018.
4
Cancer vaccines: Building a bridge over troubled waters.癌症疫苗:在波涛汹涌的海面上架起桥梁。
Cell. 2022 Jul 21;185(15):2770-2788. doi: 10.1016/j.cell.2022.06.035. Epub 2022 Jul 13.
5
Tumor-Infiltrating T Cells - A Portrait.肿瘤浸润性T细胞——一幅画像。
N Engl J Med. 2022 Mar 10;386(10):992-994. doi: 10.1056/NEJMcibr2119477.
6
Role of MBD3-SOX2 axis in residual myeloma following pomalidomide.MBD3-SOX2轴在泊马度胺治疗后残留骨髓瘤中的作用
Leukemia. 2021 Nov;35(11):3319-3323. doi: 10.1038/s41375-021-01145-0. Epub 2021 Feb 18.
7
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma.癌症免疫治疗学会关于免疫疗法治疗多发性骨髓瘤的共识声明。
J Immunother Cancer. 2020 Jul;8(2). doi: 10.1136/jitc-2020-000734.
8
Rosetting T cells in Hodgkin lymphoma are activated by immunological synapse components HLA class II and CD58.霍奇金淋巴瘤中的玫瑰花结 T 细胞被免疫突触成分 HLA Ⅱ类和 CD58 激活。
Blood. 2020 Nov 19;136(21):2437-2441. doi: 10.1182/blood.2020005546.
9
Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer.PD-L1 与 PD-1 阻断对人类癌症中髓样炎症的差异影响。
JCI Insight. 2020 Jun 18;5(12):129353. doi: 10.1172/jci.insight.129353.
10
Marrow-Infiltrating Regulatory T Cells Correlate with the Presence of Dysfunctional CD4PD-1 Cells and Inferior Survival in Patients with Newly Diagnosed Multiple Myeloma.骨髓浸润调节性 T 细胞与新诊断多发性骨髓瘤患者中功能失调的 CD4+PD-1+细胞的存在及预后不良相关。
Clin Cancer Res. 2020 Jul 1;26(13):3443-3454. doi: 10.1158/1078-0432.CCR-19-1714. Epub 2020 Mar 27.